- Home
- LUCD vs PASG Comparison
LUCD vs PASG Comparison
Compare LUCD & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- PASG
- Stock Information
- Founded
- LUCD 2018
- PASG 2017
- Country
- LUCD United States
- PASG United States
- Employees
- LUCD N/A
- PASG N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- PASG Health Care
- Exchange
- LUCD Nasdaq
- PASG Nasdaq
- Market Cap
- LUCD 38.4M
- PASG 42.2M
- IPO Year
- LUCD 2021
- PASG 2020
- Fundamental
- Price
- LUCD $0.98
- PASG $0.62
- Analyst Decision
- LUCD Strong Buy
- PASG Strong Buy
- Analyst Count
- LUCD 4
- PASG 1
- Target Price
- LUCD $3.69
- PASG $13.00
- AVG Volume (30 Days)
- LUCD 535.1K
- PASG 245.8K
- Earning Date
- LUCD 11-13-2024
- PASG 11-13-2024
- Dividend Yield
- LUCD N/A
- PASG N/A
- EPS Growth
- LUCD N/A
- PASG N/A
- EPS
- LUCD N/A
- PASG N/A
- Revenue
- LUCD $4,189,000.00
- PASG N/A
- Revenue This Year
- LUCD $88.47
- PASG N/A
- Revenue Next Year
- LUCD $238.94
- PASG N/A
- P/E Ratio
- LUCD N/A
- PASG N/A
- Revenue Growth
- LUCD 179.27
- PASG N/A
- 52 Week Low
- LUCD $0.63
- PASG $0.45
- 52 Week High
- LUCD $1.58
- PASG $1.79
- Technical
- Relative Strength Index (RSI)
- LUCD 54.35
- PASG 53.72
- Support Level
- LUCD $0.90
- PASG $0.45
- Resistance Level
- LUCD $1.12
- PASG $0.68
- Average True Range (ATR)
- LUCD 0.07
- PASG 0.08
- MACD
- LUCD -0.01
- PASG -0.00
- Stochastic Oscillator
- LUCD 36.55
- PASG 71.13
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.